Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 550-555
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.550
Table 2 Patient profile of secondary eradication therapy
| PPI group | Vonoprazan group | |
| Average age | 62.3 (19-96) | 63.6 (39-89) |
| Gender(male:female) | 182:204 | 28:38 |
| PPI | ||
| Lansoprazole | 266 | |
| Omeprazole | 1 | |
| Rabeprazole | 32 | |
| Esomeprazole | 87 | |
| Underlying disease | ||
| Chronic gastritis | 313 | 48 |
| Peptic ulcer | 44 | 8 |
| After endoscopic therapy for early gastric cancer | 28 | 10 |
| Other | 1 | 0 |
- Citation: Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2016; 7(4): 550-555
- URL: https://www.wjgnet.com/2150-5349/full/v7/i4/550.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i4.550